Problem

Doctronic targets two related healthcare bottlenecks: patients often need quick, affordable guidance for symptoms, treatment, prescriptions, or a doctor's note, while clinics spend substantial time handling routine administrative work. Its consumer-facing price point is designed to reduce the cost and friction of accessing care: patients can move from an AI assessment to a licensed online doctor in under 30 minutes for $39, with insurance also accepted.

The clearest operational wedge is prescription renewal. Renewals represent a large share of daily healthcare administration and can create delays for patients and workload for clinicians. In Utah, Doctronic is piloting AI-assisted renewal of previously prescribed medications, aiming to automate routine, guideline-based requests while preserving physician authorization and oversight.

Product / Service

Doctronic combines a free, anonymous AI medical chatbot with on-demand telehealth. Users describe their symptoms and receive a treatment plan based on peer-reviewed medical research; when they need a prescription, treatment, or doctor's note, they can escalate to a licensed physician online. The model is therefore not purely an autonomous chatbot: it uses AI for initial assessment and navigation, then offers a human clinical visit for medical decisions and documentation.

Its Utah prescription product extends the same model into clinical workflow automation. Within defined parameters, the system can process 30-, 60-, or 90-day renewals for medications already prescribed by a licensed provider, with physician oversight and safeguards against unauthorized dispensing of controlled substances. The intended benefit is faster access and better medication continuity for patients, while allowing clinicians to spend more time on higher-value care.

Market

Doctronic competes in AI-enabled primary care, symptom assessment, and consumer telehealth. The most clearly identified incumbent comparator is Teladoc: Doctronic positions its free AI visit and $39 licensed-doctor video call as a lower-cost alternative to Teladoc. Its acquisition of Summer Health in July 2026 expands the platform into pediatric care, adding an AI-triage-to-pediatrician pathway and access to more than 100,000 real-world pediatric text conversations.

The company is commercial rather than pre-revenue. In March 2026, Doctronic announced a $40 million Series B, bringing total funding above $65 million; it reported 15-fold growth to eight-figure annualized revenue, nearly three times the repeat-patient rate, and more than 300,000 unique weekly visitors. Its Utah prescribing pilot is meaningful regulatory traction, but it remained in Phase 1 and the state said robust evidence of benefits was not yet available, so the company’s long-term clinical and regulatory durability is still being established.